What was the overall market valuation of the US pediatric brain-tumor market in 2024?

The overall market valuation was $282.1 Million in 2024. Read More

What is the projected market valuation for the US pediatric brain-tumor market by 2035?

The projected valuation for 2035 is $568.25 Million. Read More

What is the expected CAGR for the US pediatric brain-tumor market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.57%. Read More

Which tumor type had the highest valuation in 2024 within the US pediatric brain-tumor market?

Brainstem Glioma had the highest valuation at $110.24 Million in 2024. Read More

What are the projected valuations for chemotherapy in the US pediatric brain-tumor market by 2035?

The projected valuation for chemotherapy is $153.68 Million by 2035. Read More

How does the market valuation for adolescents compare to that of infants in the US pediatric brain-tumor market?

In 2024, adolescents had a valuation of $122.1 Million, while infants had $40.0 Million. Read More

What is the valuation for targeted therapy in the US pediatric brain-tumor market as of 2024?

The valuation for targeted therapy was $107.53 Million in 2024. Read More

Which diagnostic method had the highest valuation in 2024 for the US pediatric brain-tumor market?

Magnetic Resonance Imaging had the highest valuation at $112.84 Million in 2024. Read More

What is the projected valuation for ependymoma treatment by 2035?

The projected valuation for ependymoma treatment is $90.0 Million by 2035. Read More

Who are the key players in the US pediatric brain-tumor market?

Key players include Novartis, Roche, Bristol-Myers Squibb, Merck & Co, Eli Lilly and Company, Amgen, Pfizer, and AstraZeneca. Read More

US Pediatric Brain Tumor Market

ID: MRFR/Pharma/17950-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Pediatric Brain Tumor Market Research Report By Tumor Type (Astrocytoma, Medulloblastoma, Ependymoma, Brainstem Glioma), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy), By Age Group (Infants, Children, Adolescents) and By Diagnosis Method (Magnetic Resonance Imaging, Computed Tomography Scan, Biopsy) - Growth & Industry Forecast 2025 To 2035

US Pediatric Brain Tumor Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Tumor Type (USD Million)
  1. 4.1.1 Astrocytoma
  2. 4.1.2 Medulloblastoma
  3. 4.1.3 Ependymoma
  4. 4.1.4 Brainstem Glioma
2. 4.2 Chemicals and Materials, BY Treatment Type (USD Million)
  1. 4.2.1 Surgery
  2. 4.2.2 Radiation Therapy
  3. 4.2.3 Chemotherapy
  4. 4.2.4 Targeted Therapy
3. 4.3 Chemicals and Materials, BY Age Group (USD Million)
  1. 4.3.1 Infants
  2. 4.3.2 Children
  3. 4.3.3 Adolescents
4. 4.4 Chemicals and Materials, BY Diagnosis Method (USD Million)
  1. 4.4.1 Magnetic Resonance Imaging
  2. 4.4.2 Computed Tomography Scan
  3. 4.4.3 Biopsy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TUMOR TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY AGE GROUP
5. 6.5 US MARKET ANALYSIS BY DIAGNOSIS METHOD
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY TUMOR TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TUMOR TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY DIAGNOSIS METHOD, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TUMOR TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.2.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Tumor Type (USD Million, 2025-2035)

Astrocytoma
Medulloblastoma
Ependymoma
Brainstem Glioma

Chemicals and Materials By Treatment Type (USD Million, 2025-2035)

Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy

Chemicals and Materials By Age Group (USD Million, 2025-2035)

Infants
Children
Adolescents

Chemicals and Materials By Diagnosis Method (USD Million, 2025-2035)

Magnetic Resonance Imaging
Computed Tomography Scan
Biopsy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”